Hossam El Benawi: Who Can Safely Stop Anticoagulation after LVT Resolution?
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: Advances, adding:
”Who Might Need Long-Term Anticoagulation After Left Ventricular Thrombus (LVT) Resolution
Much on the optimal anticoagulant for LVT resolution.
However, less is known about management after LVT resolution:
Clinical factors associated with LVT recurrence?
Echo findings predict recurrence?
Should predictors be assessed at the time of LVT diagnosis or resolution?
Most importantly?!!!!: Who can safely STOP AC after LVT resolution?
Our Mayo Clinic multi-site study (Part 2) showed that:
Among 252 patients with LVT resolution, recurrence occurred in (14.3%).
Patients with recurrent LVT were likely to have:
- Ischemic cardiomyopathy (83.3% vs 61.1%, p=0.01)
- Lower LVEF at time of LVT resolution (34.0% ± 12.4 vs 40.0% ± 15.3, p=0.04)
- LV apical aneurysm (25.0% vs 6.5%, p=0.005)
Echo at time of LVT resolution more predictive of recurrence than at diagnosis.
Adjusted Cox Analysis
Factors associated with higher risk of recurrence:
- LV apical aneurysm — HR 3.12 (1.43–6.84)
- Prior ischemic stroke — HR 2.75 (1.22–6.17)
Factors associated with lower risk of recurrence:
- Higher LVEF — HR 0.96 per 1% increase (0.95–0.99)
- Continuation of AC — HR 0.27 (0.13–0.58)
Patients with LV apical aneurysm, prior ischemic stroke, or persistently reduced LVEF benefit from prolonged AC.
The remaining question is:
Who can safely STOP AC after LVT resolution?
Stay tuned for Part 3 of Mayo Clinic multi-site LVT studies, exploring novel bed side score that help to define who can safely STOP AC post resolution?”
Title: Clinical and Echocardiographic Factors Associated With Left Ventricular Thrombus Recurrence
Authors: Kirsten M. Lipps, Hossam Elbenawi, Samuel Heller Jr., Robert D. McBane, Waldemar E. Wysokinski, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, David A. Liedl, Raymond C. Shields, Damon E. Houghton

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI